Medytox announced on the 5th that it publicly unveiled its newly developed botulinum toxin product line for the first time at the International Master Class on Aesthetic Surgery (IMCAS World Congress 2025) held in Paris, France, for three days until the 1st (local time).
Botulinum toxin is a medicine that is extracted from the bacterium Clostridium botulinum, which causes food poisoning, and it works by causing muscle paralysis to reduce wrinkles.
On the last day of IMCAS, during a special session on botulinum toxin, Sujeong Heo, director of Bundang Skin Young Clinic, revealed the development status of the new botulinum toxin products PF30 and MT951 in her lecture entitled "Botulinum Toxin Product Pipeline and Future." Eight prominent global corporations, including AbbVie and Merz, attended the session, while only Medytox and JETEMA represented domestic companies.
The company's PF30 is an improved version of the non-animal liquid botulinum toxin product "MT10109L" (generic name NivobotulinumtoxinA) in pre-filled syringe (PFS) form. The company stated that it would drastically improve convenience and accuracy in administration.
The MT951, which was also introduced, is a next-generation toxin product being developed through genetic recombination. According to the company, it showed about a 30% longer duration effect in non-clinical trials compared to other companies' toxin products. The company emphasized that PF30 and MT951 have differentiated competitiveness from existing products, making them potential game-changers in the market.
Jung Hyun-ho, CEO of Medytox, participated as a panelist in the "La Tribune" session, revealing overseas expansion strategies, including the launch plan for the liquid botulinum toxin product "MT10109L," which is set to enter the U.S. market.
MT10109L is a liquid toxin product that eliminates the use of animal-derived components throughout the entire manufacturing process, including strain cultivation and raw material production, and it does not use human serum albumin (HSA) as an excipient, thereby completely preventing the possibility of animal-derived virus contamination. CEO Jung stated, "MT10109L will enter other countries such as Europe along with the U.S. entry."
Meanwhile, IMCAS is the world's largest aesthetic surgery conference, attended by dermatology and plastic surgery experts and industry professionals from around the globe. This year, about 20,000 attendees from over 130 countries participated.